Fingerprint
Dive into the research topics of 'Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically